Omniscan Lawsuit - Manufacturer Of Omniscan Sued By Former Nurse

Send to Friend | Bookmark | Live Chat

A lawsuit was recently filed in US District Court by a former nurse charging that Omniscan was responsible for causing her to develop a serious skin and joint condition called Nephrogenic Systemic Fibrosis. This may be the first lawsuit filed against GE Healthcare, the manufacturer of Omniscan, as a result of adverse events related to the contrast agent. Omniscan, also known as Gadodiamide, is a Gadolinium based contrast agent used to enhance MRI images. The agent is injected into the patient immediately prior to an MRI or MRA procedure to help physicians distinguish blood vessels from tissue.

The lawsuit alleges that days after receiving an injection of Omniscan, the individual developed the signature symptoms of Nephrogenic Systemic Fibrosis which, in turn, developed into extensive fibrosis of the arms, legs, and associated joints. The advancement of the condition has caused numerous effects that may be permanent and could ultimately lead to her death. The individual is now wheelchair bound and is unable to move her legs, several fingers, and her elbows beyond a slight bending and extension. Because of her condition, the individual is no longer able to work as a registered nurse.

The US Food and Drug Administration has received numerous reports of individuals developing Nephrogenic Systemic Fibrosis in recent years. In 2006, the number of reports received and confirmed prompted the US Food and Drug Administration to issue a Public Health Advisory Alert detailing the facts behind patients developing this serious, life-threatening condition after exposure to Gadolinium based contrast agents, such as Omniscan. Since then, much information has been released publicly detailing the link between Gadolinium based contrast agents and the development of Nephrogenic Systemic Fibrosis.

Nephrogenic Systemic Fibrosis has been found to only affect patients with moderate to end stage kidney disease and kidney failure who receive an injection of a Gadolinium based contrast agent prior to an MRI. The condition is considered a fibrosing disorder and can affect the skin, heart, lungs, diaphragm, liver, and skeletal muscles. The skin of the patient’s extremities begins to develop dark or reddened patches that start to tighten and harden, causing the patient extreme discomfort. The tightened skin restricts the movement of the joints and eventually causes the patient to lose their mobility.

Nephrogenic Systemic Fibrosis is considered a debilitating condition and may ultimately be fatal to the affected patient. The Centers For Disease Control concluded in its report that the use of Gadolinium based contrast agents should be avoided in patients with advanced renal failure. Other health agencies have also released reports saying that the use of Gadolinium based contrast agents for MRI imaging should be avoided if the patient has moderate to end-stage kidney disease.

Main Gadolinium Content Sections

Gadolinium

Nephrogenic Systemic Fibrosis (NSF)

Nephrogenic Fibrosing Dermopathy (NFD)

Related Contents - Gadolinium, Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

What Is Gadolinium?

Gadolinium and Magnetic Resonance Imaging (MRI)

Gadolinium and MRI Safety Guidelines

Gadolinium Side Effects and Complications

Issues with MRI Contrast Agents

Gadolinium Based Contrast Agents Used With Magnetic Resonance Imaging

Gadolinium and NSF/NFD

What Is Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy?

Does Gadolinium Based Contrast Agents Cause Nephrogenic Systemic Fibrosis?

Nephrogenic Systemic Fibrosis Associated With Agents Containing Gadolinium

Devastating Condition Called Nephrogenic Systemic Fibrosis Subject Of Alert By The FDA

The Theory Behind How Gadolinium Based Contrast Agents Cause Nephrogenic Systemic Fibrosis

Nephrogenic Systemic Fibrosis and MRI Contrast Agents

Symptoms and Signs of Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

Treatment Options For Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

Dialysis May Prevent Nephrogenic Systemic Fibrosis

Risk For Nephrogenic Systemic Fibrosis in Patients With Advanced Kidney Disease

Gadolinium Based MRI Contrast Agent Section

Magnevist MRI NSF

Gadolinium Based Contrast Agent - Magnevist

Magnevist and Nephrogenic Systemic Fibrosis

MultiHance MRI NSF

Gadolinium Based Contrast Agent – MultiHance

Gadolinium Based Contrast Agent - Omniscan

Gadolinium Based Contrast Agent - OptiMARK

Gadolinium Based Contrast Agent - ProHance

>> Omniscan Lawsuit

Omniscan MRI NSF

OptiMARK MRI NSF

Prohance MRI NSF

Related Websites & Recent Gadolinium Studies

5/23/07 - FDA Press Release

2/07/07 - Study Links Gadolinium treatment to NSF

1/25/07 - MRI Contrast Agent Linked to Rare Disease

1/15/07 - Dialysis to Prevent NSF After Gadolinium Treatment

Do I have a Gadolinium Lawsuit?

The Products Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Gadolinium lawsuits. We are handling individual litigation nationwide and currently accepting new Gadolinium side effect cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field